Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

5257 - Clinical value of cfDNA and CTCs in EGFR mutations detected in advanced NSCLC.

Date

11 Sep 2017

Session

Poster display session

Presenters

Silvia Calabuig Fariñas

Citation

Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390

Authors

S. Calabuig Fariñas1, E. Jantus-Lewintre2, A. Fernández3, C. Mayo de las Casas4, A. Blasco5, C. Aguilar6, N. Jordana4, A. Balada4, M. Garzón Ibañez4, F. Zhang6, N. Dong6, M.A. Molina4, R. Rosell4, C. Camps Herrero7

Author affiliations

  • 1 Laboratorio De Oncología Molecular, Fundación Para La Investigación, Hospital General Universitario De Valencia-ciberonc, Departamento de Patología, Universitat de València., 46020 - Valencia/ES
  • 2 Laboratorio De Oncología Molecular, Fundación Para La Investigación, Hospital General Universitario De Valencia-ciberonc, Departamento de Biotecnología, Universidad Politécnica de Valencia;, 46014 - Valencia/ES
  • 3 Servicio De Oncología Médica, Hospital General Universitario Valencia, 46018 - Valencia/ES
  • 4 Laboratory Of Oncology-pangaea Oncology, H. Quirón Dexeus, 08028 - BARCELONA/ES
  • 5 Servicio De Oncología Médica, Hospital General Universitario de Valencia-CIBERONC, 46014 - Valencia/ES
  • 6 Laboratorio De Oncología Molecular, Fundación para la Investigación, Hospital General Universitario de Valencia, 46020 - Valencia/ES
  • 7 Laboratorio De Oncología Molecular, Fundación Para La Investigación, Hospital General Universitario De Valencia-ciberonc, Servicio de Oncología Médica, Hospital General Universitario de Valencia; Departamento de Medicina, Universidad de Valencia;, 46018 - Valencia/ES
More

Resources

Abstract 5257

Background

Targeted inhibition of EGFR represents a milestone in lung cancer treatment. Development of sensitive and accurate techniques allows the detection of EGFR mutations in liquid biopsies. CTCs and ctDNA analysis may be useful in treatment selection, response monitoring, and early resistance detection. The aim of this study was to correlate the EGFR mutational status of CTCs and cfDNA at diagnosis and during follow-up in non-small-cell lung cancer (NSCLC) patients.

Methods

The study included 22 EGFR mutated NSCLC patients, blood samples were collected and repeated sampling was performed during follow-up and at progression. cfDNA was obtained from plasma; whereas CTCs were isolated by size using a filtration-based device (ScreenCell), characterized and enumerated by H&E. CTC and cfDNA genotyping was performed by PNA-Taqman assay for EGFR 19del, L858R, G719X and T790M detection.

Results

Patient’s median age was 65 years, 81.8% were female, 70% never-smokers and 94% were ADC. The follow-up ranged from 3 to 48 months. Out of the 22 EGFR mutated tumors identified, 12 harbored exon 19 deletion, 7 L858R mutation in exon 21, 2 G719X mutation and one presented exon 19 deletion and T790M together at diagnosed. All patients were treated with EGFR-TKIs. 110 blood samples were evaluated at baseline and during follow-up. CTCs were observed by H&E with a range 1-30/3 ml. Our results confirm that detected mutations can provide early outcome information. Early undetectable blood mutations after EGFR-TKI might predict a large clinical response, whereas in TKI-responders patients, EGFR mutation remained undetectable, its reappearance preceded disease progression. In case of persisted mutation during treatment, a rapid progression and exitus was observed. A baseline T790M mutation in EGFR TKI-naïve patient has been reported with rapidly progression and exitus.

Conclusions

Results suggest that analyses of EGFR mutations in CTC and cfDNA have important clinical implications and can be a useful biomarker of diagnoses, response to therapy and early detection of mechanisms of TKIs resistance, in advance of clinically detection. This work was supported by Astra Zeneca (ISSRES0110), the RD12/0036/0025 ISCIII, grants from the FEDER and López-Trigo Grant.

Clinical trial identification

Legal entity responsible for the study

Fundación para la Investigación del Hospital General Universitario de Valencia

Funding

This work was supported by Astra Zeneca (ISSRES0110), the RD12/0036/0025 ISCIII, grants from the Fondo Europeo de Desarrollo Regional (FEDER) and López-Trigo Grant.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.